Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 13/20 | 0.37 |
| ▸ | EDNRA | P25101 | 13/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22021504 | 0.75 | EDNRB (0.39) | EDNRBEDNRAALDH1A1PKM | |
| SCHEMBL31475672 | 0.74 | KMT2A (0.44) | EDNRAMAPTALDH1A1 | |
| SCHEMBL22012437 | 0.71 | TP53 (0.31) | TP53 | |
| SCHEMBL21963265 | 0.71 | LMNA (0.32) | — | |
| SCHEMBL24978551 | 0.71 | — | — | |
| SCHEMBL30517142 | 0.70 | CYP2D6 (0.50) | EDNRATP53MAPTALDH1A1 | |
| SCHEMBL23851285 | 0.70 | KMT2A (0.54) | MAPTALDH1A1 | |
| SCHEMBL5655444 | 0.69 | CA2 (0.42) | — | |
| SCHEMBL24978444 | 0.69 | CA2 (0.33) | EDNRBEDNRAMAPTALDH1A1 | |
| SCHEMBL31601067 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | EDNRB 588/4885EDNRA 307/4885TP53 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.